Pricing Log in Create free account
Friday 6 November 2026 Export RXRX’s income statement to Excel — free account

Recursion Pharmaceuticals, Inc.

RXRX Healthcare Biotechnology

Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024.

Revenue
+258.5%
EPS
+39.1%
Free cash flow
+33.8%
Total debt
−99.2%

Quarter to September 2026, against a year earlier

3.59 0.09 +2.57%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−4.6×
Dividend yield
—
F-score
3/9
Altman Z
0.37
Beneish M
−1.72
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Recursion Pharmaceuticals, Inc. (RXRX) Book value per share

Alert me on Book value per share

Recursion Pharmaceuticals, Inc.'s book value per share at the end of fiscal 2025 was 2.5×, down 33.0% from 3.8× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 1.7×. Over the past ten years it has ranged from 0.5× (fiscal 2019) to 11.1× (fiscal 2020); the current reading is higher than 36% of that period. Recursion Pharmaceuticals, Inc. ranks 297th of 611 Biotechnology companies by book value per share.

Book value per share, annual

Embed this chart

Annual newest first

Period Book value per share Change
FY2025 2.5× (33.03%)
FY2024 3.8× 69.25%
FY2023 2.2× (19.44%)
FY2022 2.8× 0.00%
FY2022 2.8× (36.11%)
FY2021 4.3× 35.84%
FY2021 3.2× (71.30%)
FY2020 11.1× 661.17%
FY2020 1.5× (59.02%)
FY2019 3.6× 668.61%

Quarterly newest first

Period Book value per share Change
Sep 2026 1.7× (2.92%)
Jun 2026 1.7× (11.24%)
Mar 2026 1.9× (23.40%)
Dec 2025 2.5× 7.91%
24 more quarters

Against its own ten years

Low 0.5× High 11.1×
Ten-year median 2.8×
Current reading's percentile 36

Book value per share against peers

Company Book value per share
PVLA Palvella Therapeutics, Inc. compare 15.1×
CLDX Celldex Therapeutics, Inc. compare 9.2×
MBX MBX Biosciences, Inc. compare 8.6×
VCEL Vericel Corporation compare 7.5×
PHVS Pharvaris N.V. compare 5.1×
NAMS NewAmsterdam Pharma Company N.V. compare 5.1×
ADMA ADMA Biologics Inc compare 2.0×
RXRX Recursion Pharmaceuticals, Inc. 1.7×
BHVN Biohaven Ltd. compare −0.7×

What Book value per share is

BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.

(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))

The full definition of Book value per share →

More on RXRX